louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04235192: A Multicenter Case-control Study of Risk Factors for Premature Ejaculation in China's Shaanxi Province
Official title: A Multicenter Case-control Study of Risk Factors for Premature Ejaculation in China's Shaanxi Province
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Premature Ejaculation
Keywords: risk factor
Lead sponsor: Xijing Hospital
Sponsor class: OTHER
Collaborators: name: First Affiliated Hospital Xi'an Jiaotong University
name: Shaanxi Provincial People's Hospital
name: Xi'an No.3 Hospital
name: Shaanxi Armed Police Corps Hospital
name: Northwest Women's and Children's Hospital, Xi'an, Shaanxi
First posted: 2020-01-21
Enrollment: 1340
Sex: MALE
Minimum age (years): 18
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with premature ejaculation in the outpatient department of the hospital were the case group, while patients without premature ejaculation in the outpatient department were the control group

Brief summary: Through a multicenter case-control study on the risk factors of premature ejaculation in Shaanxi, to find out the related factors of the occurrence and development of premature ejaculation, to provide reference for personalized treatment, in order to improve the quality of sexual life of patients and partners.


Eligibility criteria: Inclusion Criteria:

* 1) case group

  1. 18-64 years old, regular sexual life \> 6 months;
  2. Self-report of premature ejaculation;
  3. Able to complete questionnaires and scale scores independently. 2) control group

  <!-- -->

  1. 18-64 years old, regular sexual life \> 6 months;
  2. Both partners are satisfied with their sexual life;
  3. Able to complete questionnaires and scale scores independently.

Exclusion Criteria:

* 1) case group

  1. Those who are unable to have sex due to genital malformation;
  2. Patients with serious cardiovascular and cerebrovascular diseases;
  3. Severe mental disorders (history of epilepsy, mania, etc.);
  4. Have a history of brain trauma;
  5. People with a long history of substance abuse. 2) control group

  <!-- -->

  1. Patients with a history of mental illness;
  2. Oral selective serotonin (5-ht) reuptake inhibitors, tricyclic antidepressants, triazolidine antidepressants, tramadol and sedatives

Primary outcomes:
measure: IELT
timeFrame: Within 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Xi'an
country: China
facility: Xijing Hospital, Fourth Military Medical University
state: Shaanxi
Study officials:
References:
Clinical trial NCT00849992: Treatment Study for Actinic Cheilitis Comparing Imiquimod 5% and Photodynamic Therapy
Official title: Randomized Prospective Study Comparing 5% Imiquimod and Photodynamic Therapy for Actinic Cheilitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Actinic Cheilitis
Keywords: Actinic cheilitis
Imiquimod 5%
Photodynamic therapy
Lead sponsor: Norwegian University of Science and Technology
Sponsor class: OTHER
Collaborators: name: St. Olavs Hospital
First posted: 2009-02-24
Enrollment: 53
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Actinic cheilitis is a common precancerous lesion of the lip. The purpose of this study is to compare imiquimod 5% therapy and photodynamic therapy. The data will include effect data, histology (skin analysis), epidemiological data and follow-up data.

Detailed description: Randomized study comparing imiquimod 5% with photodynamic therapy for actinic cheilitis. Histological, efficacy, epidemiological and clinical data will be collected.

Eligibility criteria: Inclusion Criteria:

* Clinical findings of actinic cheilitis.
* Histological findings demonstrating epithelial changes equal to or greater than mild epithelial dysplasia in severity (mild - moderate - severe).
* Age above 18.
* Willingness to take post-treatment biopsy.

Exclusion Criteria:

* Disorders predisposing to photosensitivity (porphyria, SLE).
* Pregnancy or nursing.
* Known allergy to any excipients in the study creams.
* prescribed topical retinoids, 5-fluorouracil, cryodestruction, surgical excision and curettage.

Primary outcomes:
measure: clinical and pathological complete cure rates.
timeFrame: 3 and 12 months after therapy
Secondary outcomes:
measure: clinical, safety, epidemiological and histopathological data
timeFrame: post-treatment
Other outcomes:
Locations:
city: Trondheim
country: Norway
facility: St. Olavs Hospital
Study officials:
affiliation: St. Olavs Hospital
name: Stein H Sundstrøm, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03466892: Repetitive Thinking in FibroMyalgia and Attentional Bias
Official title: RTFM-AB - Repetitive Thinking in FibroMyalgia and Attentional Bias: Links Between Attentional Bias in Later Stages of Attention and Tendency to Repetitive Thinking
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Chronic Pain
Keywords: Repetitive Negative Thinking
Rumination
Fibromyalgia
Chronic pain
Attentional Bias
Lead sponsor: Centre Hospitalier Universitaire, Amiens
Sponsor class: OTHER
First posted: 2018-03-15
Enrollment: 43
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: One group. It is a cross sectional study.

Brief summary: Theoretical models of chronic pain hypothesize a privileged treatment of pain-related information that would be the basis of avoidance behaviors in chronic pain. This privileged treatment, also called attentional bias, has been found experimentally in chronic pain. Meta-analyses confirmed that but leaded the question of the difference found between bias in period of attention orientation and bias in period of maintained attention. One of the hypotheses is to consider one or more cognitive processes that would "fix" the attention around significant perceived problems and that would hinder the attentional disengagement and the reorientation of attention towards neutral or positive stimuli. In view of the scientific literature in psychopathology but also in chronic pain we think that the negative repetitive thoughts (RNT) variable is one of these processes. So the investigators want to better understand the difference of attentional bias at different moments of the attentional process by interrogating the Repetitive Thinking variable. More specifically the investigators test the Attentional Bias hypothesis in Fibromyalgia. Patient with Fibromyalgia will be recruited at the Pain Center of CHU-Amiens. Patients will complete different scales and also the visual probe task. First, the investigators hypothesize the attention bias for pain-related information in the FM group is correlated with the level of negative repetitive thinking in the maintained attention phase. Second, the investigators hypothesize the attention bias is more important in the attention maintenance phase (1250 ms) than in the attention orientation phase (500 ms).


Eligibility criteria: Inclusion Criteria:

Adults Patients inclusion criteria:

* 1990 ACR Criteria of FM
* Free and informed consent signed.
* French mother tongue spoken, written, read.
* Major person.

Exclusion Criteria:

* Adult major under protection.
* Patient with severe psychosis or depression or severe anxiety or impulsivity as -assessed by the clinician.

Primary outcomes:
measure: To measure attentional bias using a visual probe task paradigm.
timeFrame: 1 hour and 20 min
Secondary outcomes:
Other outcomes:
Locations:
city: Amiens
country: France
facility: CHU Amiens Picardie
state: Picardie
Study officials:
References:
Clinical trial NCT00727792: Refinement and Assessment of New MRI Technologies for Thoracic/ Cardiovascular Exams
Official title: Refinement and Assessment of New MRI Technologies for Thoracic/ Cardiovascular Exams
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Magnetic Resonance Imaging (MRI) of the Chest
Keywords: participants
scheduled
clinically
ordered
MRI
Lead sponsor: University of Michigan
Sponsor class: OTHER
First posted: 2008-08-04
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of the study is to improve chest MRI exams, eventually resulting in improvements in patient care.

Detailed description: We will recruit patients to participate in the assessment of new MRI technologies designed to improve chest MRI exams that will result in improvements in patient care.

Several different MRI technologies will be evaluated. Specific evaluation of distinct technologies (eg. new head coil design, and new imaging sequence for the spine) may be evaluated simultaneously, or over non-overlapping periods in time.

Eligibility criteria: Inclusion Criteria:

* If you are a male or a non-pregnant female patient, age 18 years or older, of any ethnic background presenting to MRI for a clinically-ordered chest MRI exam, you are eligible to participate in this study.
* If you are a female of child bearing potential you will be questioned for the possibility of pregnancy. Pregnancy screening, if necessary, is performed routinely by ordering physicians prior to MRI scanning to confirm the patient is not pregnant.

Exclusion Criteria:

* Patients who have electrically, magnetically or mechanically activated implants such as heart pacemaker, magnetic surgical clips, prostheses or implanted neurological stimulator.
* Pregnant patients or patients who are nursing
* Patients who are claustrophobic.

Primary outcomes:
measure: New MRI Technologies
timeFrame: 3 years
Secondary outcomes:
Other outcomes:
Locations:
city: Ann Arbor
country: United States
facility: University of Michigan Hospital
state: Michigan
Study officials:
affiliation: University of Michigan
name: Jadranka Stojanovska, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00752492: Acceleration of Recovery From General Anesthesia - Efficacy of Isocapnic Hyperpnoea in Obese Patients Undergoing Isoflurane Anesthesia
Official title: Acceleration of Recovery From General Anesthesia - Efficacy of Isocapnic Hyperpnoea in Obese Patients Undergoing Isoflurane Anesthesia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Recovery Time From Isoflurane Anesthesia in Obese Patients
Keywords: Isocapnic hyperpnoea
obesity
isoflurane
Recovery of obese patient from isoflurane anesthesia
Lead sponsor: University Health Network, Toronto
Sponsor class: OTHER
Collaborators: name: The Physicians' Services Incorporated Foundation
First posted: 2008-09-15
Enrollment: 44
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Faster recovery from anesthesia is important for obese patients because they are at high risk of respiratory complications following tracheal extubation. Isoflurane has several properties that make it a preferable agent for anesthesia in obese patients. Its main limitation is a longer recovery time due to slower elimination in comparison to other agents. Elimination of isoflurane from the lungs can be accelerated by increasing in patient's minute ventilation, which decreases the level of CO2 in blood (hypocapnia).Isocapnic Hyperpnoea (IH) is a method allowing increased ventilation and therefore enhancement of the elimination of inhalation agents while maintaining a normal blood CO2 level. The investigators will compare recovery time from isoflurane anesthesia in obese patients during standard anesthesia management protocol (control) to a group treated with IH.


Eligibility criteria: Inclusion Criteria:

Elective gynecological or urological procedure,

* BMI \> 35 kg/m²,
* ASA I-III,
* Signed informed consent.

Exclusion Criteria:

* Lack of informed consent,
* ASA IV-V,
* Contra-indications to isoflurane anesthesia or other anesthetics included in the protocol,
* History of cardiac or respiratory disease,
* Alcohol or drug abuse,
* Psychiatric illness and/or medications.

Primary outcomes:
measure: Time from the end of anesthesia (turning isoflurane vaporizer off) to the readiness for Post Anesthesia Care Unit (PACU) discharge.
timeFrame: Intraoperatively and Post Anesthetic Care Unit
Secondary outcomes:
measure: Times from end of anesthesia to BIS exceeds 75, b) eye-opening to verbal command, c) extubation, d) readiness for leaving
timeFrame: Intraoperatively and Post Anesthetic Care Unit
measure: Sedation/Pain scores in the PACU.
timeFrame: Intraoperatively and Post Anesthetic Care Unit
measure: Change in exhaled isoflurane concentrations in the 1st hour postoperatively.
timeFrame: Intraoperatively and Post Anesthetic Care Unit
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: Toronto General Hospital
state: Ontario
Study officials:
affiliation: Toronto General Hospital, University Health Network
name: Rita Katznelson, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06029192: Diastolic Function in Myotonic Dystrophy Type 1
Official title: Diastolic Function in Myotonic Dystrophy Type 1
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Diastolic Dysfunction
Lead sponsor: Centre d'Investigation Clinique et Technologique 805
Sponsor class: OTHER
First posted: 2023-09-08
Enrollment: 500
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with myotonic dystrophy type 1 followed in a tertiary reference center.

Brief summary: Myotonic dystrophy type 1 (DM1) is a neuromuscular disorder in relation with an unstable expansion of CTG repeat. Patients with DM1 are at risk of arrhythmia and conduction disorders. Mortality are mainly related to respiratory failure and sudden death. Patients with DM1 may suffer from obesity, arterial hypertension, diabetes mellitus and sleep apnea. These comorbidities are classically associated with left ventricular diastolic dysfunction (DD) .

The investigators aim to assess the prevalence of left ventricular diastolic dysfunction in patients with myotonic dystrophy type 1 , the distribution of DD grading as well as the long-term prognosis of DM1 patients with a left ventricular diastolic dysfunction.


Eligibility criteria: Inclusion Criteria:

* patients with genetic proven myotonic dystrophy type 1
* who experienced a Doppler- Echocardiography including an assessment of the left ventricular diastolic function

Exclusion Criteria:

* wall motion basal abnormalities
* significant valvular disease

Primary outcomes:
measure: mortality
timeFrame: 7 years
Secondary outcomes:
measure: Incidence of arrhythmia
timeFrame: 7 years
measure: acute heart failure
timeFrame: 7 years
Other outcomes:
Locations:
city: Garches
country: France
facility: Hopital Raymond Poincare
Study officials:
affiliation: CHU Raymond Poincare
name: Abdallah FAYSSOIL, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00245492: Chromocolonoscopy for the Detection of Flat Adenomas in Routine Colorectal Cancer Screening.
Official title: Chromocolonoscopy for the Detection of Flat Adenomas in Routine Colorectal Cancer Screening.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Colon Cancer
Polyp
Adenoma
Keywords: Colonoscopy
Chromoscopy
Prevention
Lead sponsor: Indiana University
Sponsor class: OTHER
Collaborators: name: American College of Gastroenterology
name: Stony Brook University
name: University of Chicago
First posted: 2005-10-28
Enrollment: 792
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The proposed research aims to determine the prevalence, size, shape and histology of flat colorectal neoplasms in a cohort of asymptomatic, average-risk individuals presenting for screening colonoscopy. Patients will be randomized to either conventional colonoscopy or chromocolonoscopy, where the entire colon will be sprayed with indigocarmine dye and examined in the usual manner. The primary outcome will be the total number of adenomas detected, with special attention to the subgroup of flat and depressed lesions. To promote the generalizability of the results, neoplasms will be described according to standard Western and Japanese classification schemes.


Eligibility criteria: Inclusion Criteria:

* Patients undergoing screening colonoscopy

Exclusion Criteria:

* Age \< 50
* Prior colon resection
* Inflammatory bowel disease
* Prior colonoscopy or sigmoidoscopy
* More than one first-degree relative with colon cancer

Primary outcomes:
measure: Prevalence of adenomas detected by chromocolonoscopy versus standard colonoscopy.
timeFrame: Cross-sectional prevalence of adenomas between the 2 study groups
Secondary outcomes:
Other outcomes:
Locations:
city: Indianapolis
country: United States
facility: Indiana University
state: Indiana
city: Indianapolis
country: United States
facility: Roudebush VA Medical Center
state: Indiana
city: Stony Brook
country: United States
facility: SUNY Stony Brook
state: New York
Study officials:
affiliation: Indiana University School of Medicine, Roudebush VA Medical Center, Indianapolis, Indiana
name: Charles J Kahi, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01221792: Carvedilol Versus Placebo for Treatment in Post Traumatic Stress Disorder (PTSD)
Official title: A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Study to Assess the Safety and Efficacy of Carvedilol Versus Placebo in the Treatment of Post Traumatic Stress Disorder
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Post-Traumatic Stress Disorder
Keywords: PTSD
Anxiety
Trauma
Assault
Victim
Witness
Post Traumatic Stress Disorder
Combat veteran
Flashbacks
Nightmares
Sleep Disturbance
Hyperarousal
Numbness
Avoidance
Lead sponsor: Columbia Northwest Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2010-10-15
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The investigators hypothesize that carvedilol, at less then therapeutic doses for cardiac effect, will reduce symptoms of Post Traumatic Stress Disorder.

Detailed description: This initial proof of concept trial design is intended to explore multiple variables. Fist, it is intended to determine if carvedilol has any statistically significant effect over placebo on the various overall symptoms, symptom clusters, or individual symptoms of post traumatic stress disorder. Next, the flexible dosing trial design is aimed to detect the therapeutic dose, or dosing range for carvedilol when used in the treatment of PTSD

Eligibility criteria: Inclusion Criteria:

* Diagnosis of Post Traumatic Stress Disorder according to DSM-IV
* Must be able to speak, read and understand the English language and be able to provide written informed consent

Exclusion Criteria:

* current, unstable and significant medical condition/illness
* bronchial asthma or related bronchospastic condition
* AV block
* Sick Sinus Syndrome
* Bradycardia
* Peripheral hear disease
* Unstable thyroid disorder
* History of seizure disorder
* Females who are pregnant, lactating or planning to become pregnant
* Bipolar
* Schizophrenia
* Dementia
* Intolerance or hypersensitivity to alpha or beta blockers

Primary outcomes:
measure: Davidson Trauma Scale (DTS)
timeFrame: 5 weeks
Secondary outcomes:
measure: Clinician Administered PTSD Scale (CAPS)
timeFrame: 6 Weeks
measure: Insomnia Severity Index (ISI)
timeFrame: 5 Weeks
Other outcomes:
Locations:
city: San Diego
country: United States
facility: Artemis Institute for Clinical Research
state: California
city: Lake Charles
country: United States
facility: Lake Charles Clinical Trials
state: Louisiana
city: Bellevue
country: United States
facility: Northwest Clinical Research Center
state: Washington
Study officials:
affiliation: Columbia Northwest Pharmaceuticals, LLC
name: Arifulla Khan, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT02307292: Prospective, Post Market Surveillance Q3-registry (POLARIS)
Official title: Prospective, Non-randomized Post Market Surveillance Registry to Document the Clinical Performance in Routine Clinical Practice of the POLARIS Peripheral Vascular Self Expanding Stent System.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Peripheral Artery Disease
Keywords: Superficial femoral artery
Self Expanding Stent System
Lead sponsor: QualiMed Innovative Medizinprodukte GmbH
Sponsor class: INDUSTRY
First posted: 2014-12-04
Enrollment: 250
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with single significant (\>50%) superficial femoral artery disease

Brief summary: This is a prospective, non-randomized post market surveillance registry designed to document the clinical Performance in Routine clinical practice of the POLARIS Peripheral Vascular Self Expanding Stent System


Eligibility criteria: Inclusion Criteria:

* Age \>18 years
* Single target de novo superficial femoral artery lesion (angiographic evidence of \>50% Stenosis or occlusion) by visual estimate
* Rutherford category II-IV
* At least one patent outflow artery to the ankle.
* Patient signed the informed consent

Exclusion Criteria:

* Patient with acute or subacute Thrombus
* Patients with hyperkoagulopathy
* Patients with Stenosis or occlusion where lesion crossing with guide wire is not possible
* Pregnancy or positive pregnancy test
* Previous enrolment in this Trial or other industrial Trials
* Patient´s inability to fully cooperate with the registry protocol Patient with cancer Treatment (life expectancy less than 2 years) Patients with renal failure

Primary outcomes:
measure: Freedom from target lesion revascularization
timeFrame: at 12 months
Secondary outcomes:
measure: Binary restenosis/ reocclusion
timeFrame: at 12 months
measure: Target limb amputation at the index leg (major and minor separately)
timeFrame: at 12 months
measure: All-cause death
timeFrame: at 12 months
measure: Change in resting ankle brachial index (ABI)
timeFrame: From baseline to 12 and 24 months
measure: Change in Rutherford Classification
timeFrame: From baseline to 12 and 24 months
Other outcomes:
Locations:
city: Bad Bevensen
country: Germany
facility: HGZ Bad Bevensen, Department of Angiology
Study officials:
affiliation: Cardiovascular Center Bad Bevensen, Department of Angiology
name: Hans Krankenberg, MD,PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Thieme M, Arjumand J, Spanagel M, Tepe G, Blessing E, Kroeg B, Reichert V, Betge S, Wickenhofer R, Tessarek J, Ingwersen M, Krankenberg H. Stents With Torsional Strength for Superficial Femoral Artery Disease: The Prospective Q3-Registry. J Endovasc Ther. 2022 Dec;29(6):904-912. doi: 10.1177/15266028211067726. Epub 2022 Jan 7.